{"id":938426,"date":"2026-02-19T16:09:21","date_gmt":"2026-02-19T21:09:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/"},"modified":"2026-02-19T16:09:21","modified_gmt":"2026-02-19T21:09:21","slug":"class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/","title":{"rendered":"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky"},"content":{"rendered":"
\n

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc.<\/strong> (“Vistagen” or the “Company”) (NASDAQ: VTGN) of a class action securities lawsuit.<\/p>\n

\n CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n

\n https:\/\/zlk.com\/pslra-1\/vistagen-therapeutics-inc-lawsuit-submission-form?prid=183663&wire=3<\/a>\u00a0<\/p>\n

\n VTGN<\/strong> investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n

\n CASE DETAILS: <\/strong>According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder. On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on the primary endpoint of change on the Subjective Units of Distress Scale. In pertinent part, defendants announced the trial did not achieve its primary endpoint and there was no treatment difference between fasedienol and placebo for the secondary endpoints. Following this news, the price of Vistagen\u2019s common stock declined dramatically from a closing market of $4.36 per share on December 16, 2025 to $0.86 per share on December 17, 2025, a decline of more than 80%.<\/p>\n

\n WHAT’S NEXT? <\/strong>If you suffered a loss in Vistagen during the relevant time frame, you have until March 16, 2026<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

\n NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.<\/strong><\/p>\n

\n WHY LEVI & KORSINSKY: <\/strong>Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

\n CONTACT:<\/strong>
\n
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com<\/a>\u00a0
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/vistagen-therapeutics-inc-lawsuit-submission-form?prid=183663&wire=3\u00a0 VTGN investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or … <\/p>\n

Continue reading “Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-938426","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClass Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/vistagen-therapeutics-inc-lawsuit-submission-form?prid=183663&wire=3\u00a0 VTGN investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or … Continue reading "Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-19T21:09:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky\",\"datePublished\":\"2026-02-19T21:09:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/\"},\"wordCount\":458,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/\",\"name\":\"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=\",\"datePublished\":\"2026-02-19T21:09:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/","og_locale":"en_US","og_type":"article","og_title":"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky - Market Newsdesk","og_description":"NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/vistagen-therapeutics-inc-lawsuit-submission-form?prid=183663&wire=3\u00a0 VTGN investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or … Continue reading \"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-19T21:09:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky","datePublished":"2026-02-19T21:09:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/"},"wordCount":458,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/","name":"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=","datePublished":"2026-02-19T21:09:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NzgyNSM3NDM1MDA2IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-vistagen-therapeutics-inc-vtgn-march-16-2026-deadline-to-join-contact-levi-korsinsky-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) – March 16, 2026 Deadline to Join \u2013 Contact Levi & Korsinsky"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=938426"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938426\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=938426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=938426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=938426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}